RianCorp

03/10/2023

Dont forget to bring your laser to the NLN for calibration. We are offering special calibration pricing at the conference.

15/01/2022

Interesting news release about the use of Laser for Parkinson's disease on the News this week.

Same wavelength as our laser!
We offer unit rental if anyone wants to try.

21/05/2021

Great to see everyone at the ALA Conference on the weekend. So wonderful to finally get face to face!

22/04/2021

LOW LEVEL LASER TO HELP COVID PATIENTS

There have been a couple of reports about the use of laser for COVID patients. When you think about it, our LTU-904 has been used for inflammation and fibrotic congestion for more than 20 years, so it's not surprising that it may help COVID patients who are suffering from symptoms related to inflammation in the body.

One article from the USA reports the use of a 905nm laser, which is the same wavelength as the LTU-904. https://www.lowellsun.com/2021/04/10/local-laser-therapy-study-yields-promising-results-for-coronavirus-patients/

The hospital involved is now conducting a bigger study, under hospital ethics control. We look forward to seeing the outcomes of the study.

LOWELL — As an orthopedic surgeon, Dr. Scott Sigman might be the last person one would expect to lead a study centered around treating the lungs of COVID-19 patients. But to Sigman, who has b…

06/04/2021

We will be at the ALA Symposium in May.

Drop off your laser to Ann at the RianCorp booth for calibration.

23/03/2020

RianCorp and our service centre are currently operating as normal.

Keep an eye on our page for the announcement of a date/times for our first ever online laser presentations! There will be no cost to join us.

We hope you all stay safe and well.

17/03/2020

If you have lymphoedema (or manage certain chronic pain conditions) and are unable to travel for treatment - enquire now about our monthly rental of the LTU-904 laser for home-use. Email Helen at: sales@riancorp.com

02/12/2019

As a reminder - our service centre is closed over Christmas and we send our testing equipment away for its annual servicing from mid-Dec to mid-Jan. No laser servicing is available during this period.

02/12/2019

LOW-LEVEL LASER THERAPY FOR FIBROMYALGIA: A Systematic Review and Meta-Analysis
Yeh SW, Hong CH, Shih MC, Tam KW, Huang YH, Kuan YC.

Abstract

BACKGROUND:
Fibromyalgia is a chronic disorder characterized by widespread pain and tenderness. Low-level laser therapy (LLLT), an emerging nonpharmacological treatment, has been used for relieving musculoskeletal or neuropathic pain.

OBJECTIVE:
The objective of this review and meta-analysis was to determine the efficacy of LLLT on patients with fibromyalgia.

STUDY DESIGN:
This study involved systematic review and quantitative meta-analysis of published randomized controlled trials (RCTs).

SETTING:
This study examined all RCTs evaluating the effect of LLLT on fibromyalgia.

METHODS:
We performed a systematic review and meta-analysis of RCTs evaluating the effect of LLLT on patients with fibromyalgia. PubMed, EMBASE, and the Cochrane Library were searched for articles published before August 2018. RCTs meeting our selection criteria were included. The methodological quality of the RCTs was evaluated according to the Cochrane risk-for-bias method. Review Manager version 5.3 was used to perform the meta-analysis. The primary outcomes were the total scores on the Fibromyalgia Impact Questionnaire (FIQ), pain severity, and number of tender points. The secondary outcomes were changes in fatigue, stiffness, anxiety, and depression. Standardized mean difference (SMD), 95% confidence intervals (CI), and P values were calculated for outcome analysis.

RESULTS:
We identified 9 RCTs that included 325 fibromyalgia patients undergoing LLLT or placebo laser treatment with or without an exercise program. The meta-analysis showed that patients receiving LLLT demonstrated significantly greater improvement in their FIQ scores (SMD: 1.16; 95% CI, 0.64-1.69), pain severity (SMD: 1.18; 95% CI, 0.82-1.54), number of tender points (SMD: 1.01; 95% CI, 0.49-1.52), fatigue (SMD: 1.4; 95% CI, 0.96-1.84), stiffness (SMD: 0.92; 95% CI, 0.36-1.48), depression (SMD: 1.46; 95% CI, 0.93-2.00), and anxiety (SMD: 1.46; 95% CI, 0.45-2.47) than those receiving placebo laser. Furthermore, when compared with the standardized exercise program alone, LLLT plus the standardized exercise program provided no extra advantage in the relief of symptoms. On the other hand, the results of the only RCT using combined LLLT/LED phototherapy showed significant improvement in most outcomes except for depression when compared to placebo. When compared with pure exercise therapy, combined LLLT/LED phototherapy plus exercise therapy had additional benefits in reducing the severity of pain, number of tender points, and fatigue.

LIMITATIONS:
There were some limitations in this review, mostly because of the low-to-middle methodological quality of the selected studies; for example, there was no clear allocation process and only patients were blinded in most studies. In addition, one study used per-protocol analysis with a 20% loss to follow-up. On the other hand, the differences in laser types, energy sources, exposure times, and associated medication status in these studies may have resulted in some heterogeneity.

CONCLUSIONS:
Our results provided the most up-to-date and relevant evidence regarding the effects of LLLT in fibromyalgia. LLLT is an effective, safe, and well-tolerated treatment for fibromyalgia

Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/31151332

Full article here: https://www.painphysicianjournal.com/current/pdf?article=NjMwNA%3D%3D&journal=120

31/07/2019

About ten percent of all cancer patients suffer from lymphoedema, which produces swelling in the legs, arms and breasts. The ETH start-up Dicronis has developed an instrument for simple and early diag

15/05/2019

Dont forget to bring your laser to Sydney for calibration at the ALA

13/05/2019

Lymphoedema Impact and Prevalence – International, in Australia

Abstract

Background and Study Objective: Australia was one of nine participating countries in the epidemiology Phase
II Lymphoedema Impact and Prevalence – International (LIMPRINT) project to determine the number of
people with chronic edema (CO) in local health services.

Methods and Results: Data collection occurred through questionnaire-based interviews and clinical assessment
with provided LIMPRINT tools. Four different types of services across three states in Australia participated. A total of 222 adults participated with an age range from 22 to 102 years, and 60% were female. Site 1 included three
residential care facilities (54% of participants had swelling), site 2 was community-delivered aged care services
(24% of participants had swelling), site 3 was a hospital setting (facility-based prevalence study; 28% of participants had swelling), and site 4 was a wound treatment center (specific patient population; 100% of participants had swelling). Of those with CO or secondary lymphedema, 93% were not related to cancer, the lower limbs were affected in 51% of cases, and 18% of participants with swelling reported one or more episodes of cellulitis in the previous year. Wounds were identified in 47% (n = 105) of all participants with more than half of those with wounds coming from the dedicated wound clinic. Leg/foot ulcer was the most common type of wound (65%, n = 68).

Conclusions: Distances between services, lack of specialized services, and various state funding models
contribute to inequities in CO treatment. Understanding the high number of noncancer-related CO presentations
will assist health services to provide timely effective care and improve referral pathways.

Full article can be viewed here: https://www.liebertpub.com/doi/full/10.1089/lrb.2018.0087
PDF version here: https://www.liebertpub.com/doi/pdf/10.1089/lrb.2018.0087

25/04/2019

RianCorp will be at the ALA in Sydney this May. https://www.lymphoedema.org.au/education-&-resources/2019-ala-symposium/welcome/

Ann will be doing calibrations while there. You can drop off your laser at the RianCorp booth on the first day and pick up the next day. Contact us for pricing or for further info.

02/04/2019

RianCorp will be in Auckland, New Zealand for the Lymphoedema Therapists' Hui from April 12th-13th. Ann will be available to do calibration of your LTU-904 laser on either of those 2 days. You will need to contact us for pricing and further details.

02/04/2019

AUCKLAND, NEW ZEALAND Low Level Laser Therapy FREE Introductory Workshop

Ann Angel from RianCorp will give a presentation detailing:

* What is Low Level Laser Therapy? * Dosage and treatment * Types of laser * How does LLLT work? * Biological and physical effects * Wavelength and beams * Uses for LLLT * Research

WHEN: Friday 12th April 2019 12:00pm-1:30pm

WHERE: Epsom Apartments
1C Queen Mary Avenue Apartment 2B & 2E
Auckland, 1023, New Zealand

SPEAKER: Ann Angel – Director & Product Specialist

RSVP: By Wednesday 10th April

CPE and CPD credits may be available upon attendance of workshop (please check with your association to see if you are eligible)

For more information and bookings contact Helen: sales@riancorp.com

06/03/2019

Looking forward to visiting the USA next week.
Ill be in Seattle and Philadelphia. I have some free days. Let me know if you would like me to visit you.

04/03/2019

Registration The Information Day is for people with lymphoedema or at risk of developing it, their family and friends, health professionals or anyone interested in learning more. Registration Form – Download here Date: Saturday 9th March 2019 Time: 9:30 am – 4:00 pm (Light lunch and afternoon te...